Trends in thyroid function testing, neck ultrasound, thyroid fine needle aspiration, and thyroidectomies in North-eastern Italy

L. Dal Maso1 · C. Panato1 · A. De Paoli2 · V. Mattioli1 · D. Serraino1 · R. Elisei2 · G. Zoppini4 · C. Gobitti5 · E. Borsatti6 · E. Di Felice7 · F. Falcini8,9 · S. Ferretti10 · S. Francisci11 · P. Giorgi Rossi12 · S. Guzzinati2 · G. Mazzoleni13 · D. Pierannunzio11 · S. Piffer14 · S. Vaccarella15 · M. Vicentini12 · M. Zorzi2 · S. Franceschi1 · U. Fedeli2 · for the DEPTH Working Group

Received: 23 September 2020 / Accepted: 24 November 2020 / Published online: 18 January 2021
© The Author(s) 2021

Abstract

Purpose Evidence of an increased diagnostic pressure on thyroid has emerged over the past decades. This study aimed to provide estimates of a wide spectrum of surveillance indicators for thyroid dysfunctions and diseases in Italy.

Methods A population-based study was conducted in North-eastern Italy, including 11.7 million residents (20% of the total Italian population). Prescriptions for TSH testing, neck ultrasound or thyroid fine needle aspiration (FNA), surgical procedures, and drugs for hypo- or hyperthyroidism were extracted from regional health databases. Proportions and rates of selected examinations were calculated from 2010 to 2017, overall and by sex, calendar years, age, and region.

Results Between 2010 and 2017 in North-eastern Italy, 24.5% of women and 9.8% of men received at least one TSH test yearly. In 2017, 7.1% of women and 1.5% of men were prescribed drugs for thyroid dysfunction, 94.6% of whom for hypothyroidism. Neck ultrasound examinations were performed yearly in 6.9% of women and 4.6% of men, with a nearly two-fold variation between areas. Thyroid FNA and thyroidectomies were three-fold more frequent in women (394 and 85 per 100,000) than in men (128 and 29 per 100,000) with a marked variation between areas. Both procedures decreased consistently after 2013.

Conclusions The results of this population-based study describe recent variations over time and between surrounding areas of indicators of ‘diagnostic pressure’ on thyroid in North-eastern Italy. These results emphasize the need to harmonize practices and to reduce some procedures (e.g., neck ultrasound and total thyroidectomies) in certain areas.

Keywords Thyroid stimulation hormones (TSH) · Neck ultrasound · Fine needle aspiration · Thyroidectomies · Italy

Introduction

Thyroid diseases can be broadly summarized into thyroid dysfunctions (hypothyroidism, hyperthyroidism) and structural diseases (goiter, benign nodules, and cancer). An increased frequency of thyroid diseases has been observed over the past three decades [1–4].

National and international guidelines and recommendations about the management of thyroid diseases are available [5–7], but an abuse of testing and diagnostic procedures may lead to wasting of resources, overdiagnosis, and inappropriate treatment [8]. In addition, still open issues concern whether healthy adults can benefit from screening for thyroid diseases, including targeted screening for thyroid dysfunction in any circumstance, including pregnancy [4] and low-radiation exposures [9]. Indeed, the assessment of the
thyroid function has become common practice, in particular thyroid function testing through TSH (i.e., the most sensitive marker of thyroid status) that is increasingly included among routine tests for metabolic status or in the presence of a broad range of medical conditions [10, 11]. Concurrently, a massive increase in the neck ultrasound to explore the thyroid gland or other abnormalities of the neck has been reported in many regions of the world [12, 13], and intensity of medical surveillance has been shown to be a major determinant of the large, although heterogeneous, rise in thyroid cancer incidence over the past three decades [8, 13–22]. In particular, a very frequent detection of asymptomatic tumors, which may have never caused symptoms or harm, emerged. In addition, an increased search for cancers (incidental microcarcinomas) in patients undergoing surgery for benign thyroid diseases has been observed [12, 23–25].

Given the high and increasing thyroid cancer incidence reported in Italy [26], with progressively increasing geographic variation [27], and paucity of population-based studies describing the changes over time of ‘diagnostic pressure’ on thyroid [12, 22, 24, 28–31], this study aimed to provide population-based estimates of the frequency and trends of a wide spectrum of medical surveillance indicators for thyroid dysfunction and disease in North-eastern Italy. We explored the variations of thyroid function testing, chronic treatments, neck ultrasound, thyroid fine needle aspiration (FNA), frequency and type of thyroid surgery by sex, over time, and between areas.

**Materials and methods**

This population-based study was conducted to identify the frequency of thyroid examinations in North-eastern Italy, three administrative regions—Veneto, Emilia-Romagna, and Friuli Venezia Giulia—and two autonomous provinces—Trentino and Alto Adige (Table 1), for a total of 11.7 million residents in 2017 (20% of the total Italian population, 5.7 million men and 6.0 million women). Well comparable and comprehensive regional health system databases are active in this part of Italy, including exhaustive information on medical prescriptions and procedures since the 1990s, and regional population-based cancer registries [26]. The following databases collected by regional health authorities were examined: outpatient services databases; hospital discharge databases; and drug prescriptions databases (Online Appendix 1). Prescriptions for TSH testing (ICD9-CM code 90.42.1) [32], neck ultrasound examinations (ICD9-CM codes 88.71.4, 88.71.5, 88.73.5); and thyroid FNA (i.e., FNA biopsy or FNA cytology, ICD9-CM codes 06.01, 06.01.1, 06.11.1, 06.11.2) were retrieved from outpatient

| Table 1 | Regions included in the study, population, and proportion of people who underwent selected thyroid examinations at least once in any year. North-eastern Italy, 2010–2017 |
| --- | --- | --- | --- | --- | --- | --- |
| Population | Drugs for hypo- | TSH | Neck ultrasound | Thyroid fine | Thyroidecto- | Thyroid cancerb |
| | hyperthyroidisma | | | needle aspiration | mies | |
| | Million Mean Agec | Per 100 | Per 100,000 | | | |
| Region | 2017 | 2010–2017d | 2010–2017d | 2010–2017d | 2010–2017d | 2010–2012 |
| | Men | Women | Men | Women | Men | Women | Men | Women | Men | Women |
| Total | 11.65 | 45.5 | 1.5 | 7.1 | 9.8 | 24.5 | 4.6 | 6.9 | 128 | 394 | 29 | 85 | 10 | 21 |
| Veneto | 4.91 | 45.1 | 1.1 | 5.5 | 8.7 | 22.6 | 4.3 | 6.1 | 106 | 327 | 28 | 86 | 8 | 21 |
| Emilia-Romagna (ER) | 4.46 | 45.9 | 1.8 | 8.5 | 11.2 | 27.0 | 5.2 | 8.2 | 172 | 536 | 35 | 95 | 15 | 24 |
| Friuli Venezia Giulia (FVG) | 1.22 | 47.1 | 1.5 | 7.9 | 8.1 | 21.5 | 3.7 | 5.4 | 107 | 354 | 21 | 65 | 7 | 18 |
| Trentino | 0.54 | 44.2 | 1.6 | 8.2 | 10.8 | 31.0 | 5.6 | 8.2 | 71 | 205 | 16 | 49 | 6 | 18 |
| Alto Adige/South Tyrol (AA) | 0.53 | 42.5 | 1.5 | 6.7 | 10.6 | 22.3 | 2.9 | 4.3 | 70 | 78 | 27 | 77 | 5 | 11 |

aAt least two drug prescriptions in 2017
bAdapted from Dal Maso et al. [26], age 0–84 years
chttp://dati.istat.it/Index.aspx?DataSetCode=DCIS_INDEMOG1#
dAverage number of people undergoing each test or procedure at least once per year
services databases in each year from 2010 to 2017 by area, sex, and age.

Surgical procedures, including partial (ICD9-CM codes 06.2, 06.3x, 06.51) [33] and total (ICD9-CM codes 06.4, 06.50, 06.52) thyroidectomies for any indication were extracted from hospital discharge databases for each year between 2010 and 2017 by area, sex, and age. The number of FNA was also extracted from Hospital Discharge databases. For each individual only one procedure of TSH testing, neck ultrasound, thyroid FNA, and thyroidectomy per year was counted.

In order to characterize the prevalence of people living with “chronic” thyroid dysfunction, including hyperthyroidism or hypothyroidism (for all reasons, including thyroidectomies), individuals with at least two prescriptions for thyroid (ATC code H03AA) [34] and anti-thyroid (code H03BB) preparations were identified in 2017 from the drug prescriptions databases.

On account of the descriptive purpose of the present research and the demographic similarities of the examined regions, we computed only crude proportions and rates of selected examinations from 2010 to 2017, overall and by sex, calendar years, age, and region.

Results

In 2017, 7.1% of women and 1.5% of men living in northeastern Italy were prescribed, at least twice, drugs for hypothyroidism or hyperthyroidism (Table 1). Drugs use increased linearly with age until 65–74 years in women (13.1%) and 75 years or older in men (4.0%) (Fig. 1). The vast majority (94.6%) of these prescriptions were thyroid hormones (mainly levotiroxine) for hypothyroidism, the remaining 5.4% were thyroid inhibitors (mainly thiamazole, also known as methimazole) used to treat hyperthyroidism. The highest proportions of drugs for hypo/hyperthyroidism emerged in Emilia Romagna (8.5% in women and 1.8% in men) (Table 1).

Between 2010 and 2017, 24.5% of women and 9.8% of men received at least one prescription for TSH testing each year (Table 1). No substantial variations over time were found in either men or women (Fig. 2). The frequency of TSH testing reached >20% of women aged 25 years or older, with values exceeding 35% at 65–74 years. A more gradual increase with age was found for men, among whom TSH testing was performed >10% yearly after 65 years and >20% in those aged 75–84 years. The only remarkable geographical variation was found in Trentino where, among women aged 25–34, nearly 40% were tested for TSH yearly, i.e., approximately two-fold more than in other areas (Online Appendix 2).

The annual number of thyroidectomies was approximately three-fold higher in women (85 per 100,000) than in men (29 per 100,000) (Table 1), with a tendency to decline after 2014. Thyroidectomies increased with age, reaching a plateau at 45–74 years in women and at 55–74 years in men (Fig. 2). Total thyroidectomies were 71 per 100,000 women in 2010, 73 per 100,000 in 2013 and 2014, decreasing to 61 per 100,000 women in 2017 (Fig. 3). Partial thyroidectomies were 16 per 100,000 women in 2010 and 19 per 100,000 women in 2017. Men also showed a decrease in the frequency of total thyroidectomies from 2013 to 2017 (23 and 20 per 100,000 men, respectively) and an increase of partial

![Fig. 1 People to whom drugs for hypothyroidism or hyperthyroidism were prescribed at least twice in 2017, by sex and age group. Northwestern Italy](image-url)
Fig. 2 Rates of TSH, neck ultrasound, thyroid fine needle aspiration, and thyroidectomy (any type) by calendar year, sex, and age group. Northeastern Italy, 2010–2017
thyroidectomies from 2012 to 2017 (6.4 and 7.8 per 100,000 men). Notably, the frequency of thyroidectomies was also two-fold higher in Emilia Romagna than in Trentino in both sexes (Online Appendix 2). In women, total thyroidectomies represented more than 75% of all thyroidectomies throughout the examined period, with one partial thyroidectomy every 4.3 total thyroidectomies in 2010, increasing to 4.8 in 2013 (83%), but declining to one partial thyroidectomy every 3.3 total thyroidectomies in 2017 (77%). In men, 3.3 total thyroidectomies were performed for every partial thyroidectomy in 2011 (77%) and 2.5 in 2017 (71%).

The relative frequency of selected procedures was also shown as the ratio of neck ultrasound to FNA and FNA to thyroidectomy (Fig. 4). In women, one FNA was performed every 15.4 neck ultrasound examinations in 2010, increasing to 21.0 in 2017. In men this ratio was two-fold higher, one FNA was performed every 34 neck ultrasound examinations in 2010 and every 40 in 2017. The FNA to thyroidectomy ratios were similar in men and women (i.e., approximately one thyroidectomy every 4.5 FNA), showing negligible variations over time.

**Discussion**

This study provides the first population-based evaluation of annual rates of thyroid function testing, neck ultrasound, FNA, and thyroidectomies in 2010–2017 in North-eastern Italy, an area with nearly 12 million inhabitants, 20% of the Italian population.

We found that a large proportion of individuals living in North-eastern Italy underwent thyroid function testing. The percentages of individuals who were tested for TSH at least once per year (25% in women and 10% in men) were consistent with those reported in other countries, such as France [14], Canada [35], UK [36], and Australia [10]. Particularly high frequency of TSH testing was reported in women...
in Trentino (31% overall and 33% since age 25–34 years, Online Appendix 2), providing confirmation of local variability of thyroid function testing shown elsewhere [36].

Our indirect estimates of the proportion of individuals who received treatments for hypo- (4.1%) or hyperthyroidism (0.23%) in 2017 (4.3% overall) were similar to those obtained elsewhere using a population-based design. In the United Kingdom, the prevalence of treated hypothyroidism increased from 2.3% in 2005 to 3.5% in 2014 [37]. A survey in Spain showed that 4.2% of the population was treated for hypothyroidism and 0.8% for hyperthyroidism [38], while in the USA thyroid hormones (i.e., levotyroxine) were prescribed to 6.4% of adults in 2011–2012 [39]. The association between thyroid dysfunctions and thyroid cancers has received increasing attention [40], but a causal link with thyroid cancer has been firmly established only for nodules [41], while it is still controversial for goiter, hypo- or hyperthyroidism [42].

The frequency of annual neck ultrasound examinations we found (7% in women and 5% in men) was even higher than that reported in other studies, i.e., 2–3% in France [14], 1.5% in USA [13], and 1% in Canada [43]. Of note, thyroid nodules are often incidental findings as neck ultrasound is performed for the examination of carotid arteries (i.e., diseases unrelated to thyroid) and there was a two-fold higher frequency of thyroid FNA per neck ultrasound in women than men.

Our estimates of annual FNA (128 per 100,000 men and 394 per 100,000 women) are also higher than those reported in the only comparable population-based study in France (i.e., approximately 200 FNA per 100,000 population, men and women combined) [14]. Interestingly, FNA is the examination that shows the largest variation (i.e., > two-fold) across study areas. The decrease of FNA in the study period was more marked in the study area with the highest yearly rates (i.e., Emilia Romagna, Online Appendix 2). Information on overall reduction of FNA with substantially unchanged rates of neck ultrasound may suggest a more stringent selection of nodules that needed further examination during the last study years.

The number of thyroidectomies in North-eastern Italy for any indication between 2010 and 2017 (29 per 100,000 men and 85 per 100,000 women per year, 58 per 100,000 overall) was similar to the results reported in France [14] and the United States [25], until 2012 and 2014. Notably, in our study the frequency of total thyroidectomies has shown a downward trend since 2015, probably as a consequence of the reduction of FNA since 2015 and according to the most recent guidelines recommending that only > 1 cm nodules should be evaluated, since they have a greater potential to be clinically significant cancers [5]. In addition, after 2015 we observed a more conservative surgery approach with low but increasing rates of partial thyroidectomies. These findings could mirror, to some extent, the cultural trend induced by the worldwide steep increase of papillary microcarcinoma, in favor of a less aggressive diagnostic attitude towards small thyroid tumors. This trend culminated in the contents of 2015 ATA guidelines [5], which include a recommendation against FNA for < 10 mm diameter thyroid nodules, even when suspicious on ultrasound basis. The ATA guidelines were preceded by meeting sessions, editorials as well as review articles which anticipated this less aggressive vision [5].

Italy is one of the countries where the burden of thyroid cancer incidence and overdiagnosis is among the largest worldwide [19, 26] and the areas in the present study include the highest and lowest thyroid cancer incidence rates in Italy [26]. In North-eastern Italy, persons living after a thyroid cancer diagnosis were 0.2% of the overall population in 2010.
been explored in Canada [46], showing a relatively high stenosis). Recently, patterns of TSH testing, the most common (e.g., carotid sonography for thyroid screening reached coverage > 15% in some South Korean regions and is 3- to 4-fold higher than the frequency of neck ultrasound recorded in our study. No favourable effect of screening on thyroid cancer mortality emerged [16, 20].

Strengths of the presents study include the population-based design, the inclusion of a substantial part of Italian population, and the availability of data until 2017. Study limitations are the lack of linkage individuals for different tests performed, and of information on the determinants of examinations and their appropriateness according to current guidelines. In addition, we could not assess the outcomes of examinations performed.

Our results are not meant to recommend ideal testing frequency for TSH, neck ultrasound, or thyroid FNA in our, as well as in other populations [8]. Several comorbidities other than known or suspected thyroid diseases may have prompted TSH testing (e.g., type 2 diabetes or hypertension) [11] and neck ultrasound examination (e.g., carotid stenosis). Recently, patterns of TSH testing, the most commonly prescribed thyroid examination by clinicians, have been explored in Canada [46], showing a relatively high proportion (22%) of TSH testing not conforming to current test-ordering guidelines. Moreover, benign thyroid nodules can be safely followed with less intense protocols than those proposed in the past years [47].

In the paucity of population-based data on the appropriateness of current practice of thyroid clinical impact of test overuse or underuse [11, 48], future studies linking individual number of different thyroid examinations would be of great interest, particularly in specific population subgroups (women < 25 years, the elderly population). These studies would further increase the knowledge on the pathways to the diagnosis of thyroid cancer and other thyroid disorders, to differentiate clinically relevant diseases from those with no impact on mortality [19, 49]. In addition, they would contribute to evaluate adherence to evolving guidelines [5, 7, 50] and they should be used to reduce unnecessary medicalization of patients [51] and unnecessary costs for the healthcare system [23, 52, 53].

Conclusion

Variations in the frequency of thyroid examination across otherwise rather similar Italian regions suggest the need for a reappraisal of the indications for the detection and management of thyroid disorders. There is certainly room for a reduction of FNA examinations in some areas. According to growing evidence suggesting the feasibility of more conservative surgical approaches [54], indications to total thyroidectomy may be reconsidered. Most of all, the evidence of a first impact of recent recommendations [7, 55, 56] on thyroid diagnosis and treatments in real-life clinical practice stresses the need of further dissemination efforts, sharing, and implementation of emerging evidence-based guidelines.

Acknowledgements The authors thank Mrs. Luigina Mei for editorial assistance. Members of the Diagnostic Examinations and Pathway of THYroid diseases (DEPTH) working group: Francesco Avossa (Epidemiological Department, Azienda Zero, Padua); Rossana De Palma (Emilia Romagna Region); Rosa Vattioni (Romagna Cancer Registry); Andrea Polverino (Trento Province); Fabio Vittadello (South Tyrol Cancer Registry); Federica Toffolutti, Giuseppe Fanetti (CRO, Aviano).

Funding This work was supported by the Italian Association for Cancer Research (AIRC) (Grant no. 16921) and by the Italian Ministry of Health (Ricerca Corrente, RCR-2020-23670066, Alliance Against Cancer: Overdiagnosis, overtreatment, and outcome in cancer patients, WP 7). The funding sources had no involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

Data availability Dataset supporting our findings is available, upon reasonable request, by the corresponding author.

Compliance with ethical standards

Conflict of interest The authors have declared no competing interests.

Ethics approval and consent to participate The Italian legislation identifies regional health authorities as collectors of personal data for surveillance purposes without explicit individual consent. The approval of a research ethic committee is not required, since this study is a descriptive analysis of anonymous aggregate data without any direct or indirect intervention on patients (Decreto del Presidente del Consiglio dei Ministri, 3/3/2017, Identificazione dei sistemi di sorveglianza e dei registri di mortalità, di tumori e di altre patologie, 17A03142, GU Serie Generale n.109 del 12-05-2017). Available at: http://www.gazzettaufficiale.it/eli/id/2017/05/12/17A03142/sg, last access: 15/07/2020.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not
References

1. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW (2009) Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 94:1853–1878

2. Garmenda Madariaga AG, Santos Palacios S, Guillon-Grima F, Galofre JC (2014) The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 99:923–931

3. Walsh JP (2016) Managing thyroid disease in general practice. Med J Aust 205:179–184

4. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM et al (2018) Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 14:301–316

5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nishisho I et al (2016) American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133

6. Gharib H, Papini E, Garber JR, Duick DS, Hegedüs L et al (2016) Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 update. Endocr Pract 22:622–639

7. Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro MA, De Palma M et al (2018) Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J Endocrinol Invest 41:849–876

8. Hall SF, Webber C, Groome PA, Booth CM, Nguyen P, DeWit Y (2019) Do doctors who order more routine medical tests diagnose more cancers? A population-based study from Ontario Canada. Cancer Med 8:850–859

9. IARC Expert Group on Thyroid Health Monitoring after Nuclear Accidents (2018) Thyroid health monitoring after nuclear accidents, vol 46. IARC Technical Publications, Lyon

10. Hong A, Stokes B, Otahal P, Owens D, Burgess JR (2017) Temporal trends in thyroid-stimulating hormone (TSH) and thyroid peroxidase antibody (ATPO) testing across two phases of iodine fortification in Tasmania (1995–2013). Clin Endocrinol (Oxf) 87:386–393

11. Werhun A, Hamilton W (2015) Thyroid function testing in primary care: overused and under-evidenced? A study examining which clinical features correspond to an abnormal thyroid function result. Fam Pract 32:187–191

12. Brito JP, Al Nofal A, Montori VM, Hay ID, Morris JC (2015) The impact of subclinical disease and mechanism of detection on the rise in thyroid cancer incidence: a population-based study in Olmsted County, Minnesota during 1935 through 2012. Thyroid 25:999–1007

13. Haymart MR, Banerjee M, Reyes-Gastelum D, Caoli E, Norton EC (2019) Thyroid ultrasound and the increase in diagnosis of low-risk thyroid cancer. J Clin Endocrinol Metab 104:785–792

14. Mathonnet M, Cuerq A, Tresallet C, Thalabard JC, Fery-Lemonnier E, Russ G et al (2017) What is the care pathway of patients who undergo thyroid surgery in France and its potential pitfalls? A national cohort. BMJ Open 7:e013589

15. Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S (2015) The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. Thyroid 25:1127–1136

16. Ahn HS, Kim HJ, Kim KH, Lee YS, Han SJ, Kim Y et al (2016) Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid 26:1535–1540

17. Lin JS, Bowles EJA, Williams SB, Morrison CC (2017) Screening for thyroid cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 317:1888–1903

18. Lortet-Tieulent J, Franceschi S, Dal Maso L, Vaccarella S (2019) Thyroid cancer “epidemic” also occurs in low- and middle-income countries. Int J Cancer 144:2082–2087

19. Li M, Dal Maso L, Vaccarella S (2020) Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol 8:468–470

20. Jun JK, Hwang SY, Hong S, Suh M, Choi KS, Jung KW (2020) Association of screening by thyroid ultrasonography with mortality in thyroid cancer: a case-control study using data from two national surveys. Thyroid 30:396–400

21. Colbeth HL, Genere N, Hall CB, Jaber N, Brito JP, El Kawkaw OM et al (2020) Evaluation of medical surveillance and incidence of post-September 11, 2001, thyroid cancer in world trade center-exposed firefighters and emergency medical service workers. JAMA Intern Med 180:888–895

22. Sosa JA, Hanna JW, Robinson KA, Lamman RB (2013) Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery 154:1420–1426

23. Ho TW, Shaheen AA, Dixon E, Harvey A (2011) Utilization of thyroideology for benign disease in the United States: a 15-year population-based study. Am J Surg 201:570–574

24. Pelizzo MR, Rubello D, Bernardi C, Gemo G, Bertarella L, Schievano E et al (2014) Thyroid surgical practices shaping thyroid cancer incidence in North-Eastern Italy. Biomed Pharmacother 68:39–43

25. Francis DO, Randolph G, Davies L (2017) Nationwide variation in rates of thyroideology among US medicare beneficiaries. JAMA Otolaryngol Head Neck Surg 143:1122–1125

26. Dal Maso L, Panato C, Franceschi S, Serraino D, Buzzoni C, Busco S et al (2018) The impact of overdiagnosis on thyroid cancer epidemic in Italy, 1998–2012. Eur J Cancer 49:6–15

27. Lise M, Franceschi S, Buzzoni C, Zambon P, Falcini F, Crocetti E et al (2012) Changes in the incidence of thyroid cancer between 1991 and 2005 in Italy: a geographical analysis. Thyroid 22:27–34

28. Busco S, Giorgi Rossi P, Sperduti L, Pezzotti P, Buzzoni C, Panizzo F (2013) Increased incidence of thyroid cancer in Latina, Italy: a possible role of detection of subclinical disease. Cancer Epidemiol 37:262–269

29. Van den Brul A, Francart J, Dubois C, Adam M, Vlayen J, De Schutter H et al (2013) Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management. J Clin Endocrinol Metab 98:4063–4071

30. Panato C, Serraino D, De Santis E, Forgiairini O, Angelin T, Bidoli E et al (2019) Thyroid cancer in Friuli Venezia Giulia, northeastern Italy: incidence, overdiagnosis, and impact of type of surgery on survival. Tumori J 105:296–303

31. Rahman ST, McLeod DSA, Pandeyy N, Neale RE, Buin CJ, Baade P et al (2019) Understanding pathways to the diagnosis of thyroid cancer: are there ways we can reduce over-diagnosis? Thyroid 29:341–348

32. Ministero della Salute. Il nuovo nomenclatore: DPCM 12 gen- naio 2017. http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=1767&area=programmazioneSanitaria&menu=vuoto. Accessed 4 Nov 2020
33. Centers for Disease Control and Prevention. International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). https://www.cdc.gov/nchs/icd/icd9cm.htm. Published 2016. Accessed 4 Nov 2020

34. WHO Collaborating Centre for Drug Statistics Methodology (2018) ATC classification index with DDDs, 2019. Oslo, Norway

35. Wintemute K, Greiver M, Mclusaw W, Del Giudice ME, Sullivan F, Aliarzadeh B et al (2019) Choosing wisely Canada campaign associated with less overuse of thyroid testing: retrospective parallel cohort study. Can Fam Phys 65:e487–e496

36. Vaidya B, Ukoumunne OC, Shuttleworth J, Bromley A, Lewis A, Hyde C et al (2013) Variability in thyroid hormone test requests across general practices in south-west England. Qual Prim Care 21:143–148

37. Razvi S, Kovereav TIM, Taylor P (2019) Trends, determinants, and associations of treated hypothyroidism in the United Kingdom, 2005–2014. Thyroid 29:174–182

38. Valdés S, Maldonado-Araque C, Lago-Sampedro A, Lillo JA, Garcia-Fuentes E, Perez-Valero V et al (2017) Population-based national prevalence of thyroid dysfunction in Spain and associated factors: diabetes study. Thyroid 27:156–166

39. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL (2015) Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 314:1818–1831

40. Tran TV, Kitahara CM, de Vathaire F, Boutron-Ruault MC, Journy N (2016) Thyroid-stimulating hormone tests for identifying primary hypothyroidism: the EPIC study. J Natl Cancer Inst 108:dju097. https://doi.org/10.1093/jnci/dju097

41. Botta L et al (2019) Prognosis of long-term cancer survivors: a population-based estimation. Cancer Med 8:4497–4507

42. Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Østergaard JN, Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ et al (1999) A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 10:583–595

43. Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Østergaard JN, Overvad K et al (2014) Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst 106:dju097. https://doi.org/10.1093/jnci/dju097

44. Hall SF, Irish J, Groome P, Griffiths R (2014) Access, excess, and overdiagnosis: the case for thyroid cancer. Cancer Med 3:154–161

45. AIRTUM Working Group (2014) Italian cancer figures, report 2014: prevalence and cure of cancer in Italy. Epidemiol Prev 38(Suppl 1):1–122

46. Dal Maso L, Panato C, Guzzinati S, Serraino D, Francisci S, Botta L et al (2019) Prognosis of long-term cancer survivors: a population-based estimation. Cancer Med 8:4497–4507

47. Grani G, Lamartina L, Biifoni M, Giacomelli L, Maranghi M, Falcone R et al (2018) Sonographically estimated risks of malignancy for thyroid nodules computed with five standard classification systems: changes over time and their relation to malignancy. Thyroid 28:1190–1197

48. O’Sullivan JW, Albassiri A, Nicholson BD, Perera R, Aronson JK, Roberts N et al (2018) Overtesting and undertesting in primary care: a systematic review and meta-analysis. BMJ Open 8:e018557

49. Journey NMY, Bernier MO, Doody MM, Alexander BH, Linet MS, Kitahara CM (2017) Hyperthyroidism, hypothyroidism, and cause-specific mortality in a large cohort of women. Thyroid 27:1001–1010

50. Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngú R, Leenhart L (2017) European Thyroid Association guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: the EUITRADS. Eur Thyroid J 6:225–237

51. Jensen CB, Saukce MC, Francis DO, Voils CI, Pitt SC (2020) From overdiagnosis to overtreatment of low-risk thyroid cancer: a thematic analysis of attitudes and beliefs of endocrinologists, surgeons, and patients. Thyroid 30:696–703

52. Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen Y, Economopoulous KP et al (2014) Annual financial impact of well differentiated thyroid cancer care in the United States. Cancer 120:1345–1352

53. Kiel S, Iltermann M, Völzke H, Chenot JF, Angelow A (2020) Frequency of thyroid function tests and examinations in participants of a population-based study. BMC Health Serv Res 20(1):70

54. Molinaro E, Campopiano MC, Pieruzzi L, Matrone A, Agate L, Bottici V et al (2020) Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian center. J Clin Endocrinol Metab 105:dgz113. https://doi.org/10.1210/clinem/dgz113

55. Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teeffy SA et al (2017) ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol 14:587–595

56. Lamartina L, Durante C, Lucisano G, Grani G, Bellantone R, Lombardi CP et al (2017) Are evidence-based guidelines reflected in clinical practice? An analysis of prospectively collected data of the Italian Thyroid Cancer Observatory. Thyroid 27:1490–1497

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

L. Dal Maso1 · C. Panato1 · A. De Paoli2 · V. Mattioli1 · D. Serraino1 · R. Elisei3 · G. Zoppini4 · C. Gobitti5 · E. Borsatti6 · E. Di Felice7 · F. Falcini8,9 · S. Ferretti10 · S. Francisci11 · P. Giorgi Rossi12 · S. Guzzinati2 · G. Mazzoleni13 · D. Pierannunzio11 · S. Piffer14 · S. Vaccarella15 · M. Vicentini12 · M. Zorzi2 · S. Franceschi1 · U. Fedeli4 · for the DEPTH Working Group

1 Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via Franco Gallini 2, 33081 Aviano, PN, Italy

2 Epidemiological Department, Azienda Zero, Via J. Avanzo, 35, 35132 Padua, Italy

3 Unit of Endocrinology, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy

4 Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy
Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy

Nuclear Medicine Unit, CRO Aviano National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano, Italy

Authority for Healthcare and Welfare, Emilia Romagna Regional Health Service, Bologna, Italy

Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy

Azienda Usl della Romagna, Forlì, Italy

Ferrara Cancer Registry, University of Ferrara, Azienda USL Ferrara, Ferrara, Italy

National Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy

Reggio Emilia Cancer Registry, Epidemiology Unit, AUSL ASMN-IRCCS, Azienda USL di Reggio Emilia, Reggio Emilia, Italy

South Tyrol Cancer Registry, Bolzano, Italy

Trento Province Cancer Registry, Unit of Clinical Epidemiology, Trento, Italy

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France